Relamorelin: Completed Phase IIb enrollment

Rhythm’s Motus Therapeutics Inc. subsidiary completed enrollment of 396 patients in a double-blind, placebo-controlled, international Phase IIb trial evaluating 10, 30 and 100 ug subcutaneous relamorelin twice daily for 12 weeks. Motus has exclusive, worldwide rights to relamorelin from Ipsen (see BioCentury, March 15, 2010). ...